In our study, VEGFR2 TK (cediranib) fully inhibited VEGF-dependent VEGFR2 proliferation in NSCLC cells, whereas MAPK inhibitor (AZD6244) was not effective. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.